# Safety of TY027, a Treatment for COVID-19, in Humans

> **NCT04429529** · PHASE1 · COMPLETED · sponsor: **Tychan Pte Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Coronavirus Disease-2019 (COVID-19)

## Interventions

- **BIOLOGICAL:** TY027
- **OTHER:** 0.9% Saline

## Key facts

- **NCT ID:** NCT04429529
- **Lead sponsor:** Tychan Pte Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-09
- **Primary completion:** 2020-11-19
- **Final completion:** 2021-01-20
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04429529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04429529, "Safety of TY027, a Treatment for COVID-19, in Humans". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04429529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*